Tags Archives: cardiogenic shock

Perfusfind S.L.

Abstract Introduction Temporary mechanical circulatory support (tMCS) has become essential in managing severe cardiac dysfunction, particularly refractory cardiogenic shock (CS). Despite widespread adoption, the optimal use of tMCS is often..

Perfusfind S.L.

Abstract Time is critical in the diagnosis and treatment of cardiogenic shock, even more so than in septic shock. Early identification enables prompt circulatory support and restoration of tissue oxygenation. Baseline..

Perfusfind S.L.

Abstract Background The microaxial flow pump (mAFP) has demonstrated improved outcomes in selected patients with ST-segment elevation acute myocardial infarction and cardiogenic shock (STEMI-CS). However, its use has been associated..

Perfusfind S.L.

Abstract The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasing worldwide. Patients with cardiogenic shock were the first indication for VA-ECMO according to the Extracorporeal Life Support Organization (ELSO)..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) remains a high-mortality condition that demands rapid diagnosis, coordinated multidisciplinary management, and timely initiation of mechanical circulatory support. As more institutions implement dedicated CS teams, substantial..

Perfusfind S.L.

Abstract Context: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-sustaining therapy for severe refractory cardiogenic shock. Although VA-ECMO provides various degrees of cardiopulmonary support, mortality rates remain high. Serum biomarkers have..

Perfusfind S.L.

Abstract Managing refractory cardiogenic shock is individualized, with few aspects considered routine or universally contraindicated. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support strategy, providing hemodynamic stabilization..

Perfusfind S.L.

Abstract Importance  Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited. Objective  To assess whether early administration of levosimendan reduces the time to..

Perfusfind S.L.

Abstract Background For decades, the intra-aortic balloon pump (IABP) has been a reliable and readily available pillar of therapy for cardiogenic shock (CS). However, no clinical markers have been validated..

Perfusfind S.L.

Abstract Background Immediate initiation of extracorporeal membrane oxygenation (ECMO) has not demonstrated benefit in individuals diagnosed with cardiogenic shock based on the presence of hypotension. The relationship between other hemodynamic..

Perfusfind S.L.

Abstract Background: The use of temporary mechanical circulatory support (tMCS) has revolutionized the management of cardiogenic shock (CS). However, standardized readiness-to-explant criteria for venoarterial extracorporeal membrane oxygenation (VA-ECMO) have not been..

Perfusfind S.L.

Abstract Background/Objectives: Mechanical circulatory support (MCS) is increasingly utilized for the management of acute decompensated heart failure (HF) and cardiogenic shock (CS). The primary goals of MCS are to restore systemic..

Perfusfind S.L.

Abstract Background Active mechanical circulatory support (MCS) is associated with high complication rates. Reducing device-related complications may improve outcomes in patients with infarct-related cardiogenic shock (AMI-CS). This study aims to..

Perfusfind S.L.

Abstract Background The experience of a percutaneous microaxial (Impella)  in children with  is limited. The primary objective of this study was to review our institutional clinical outcomes of Impella use in children..

Perfusfind S.L.

Abstract Background The identification, triage, and management of cardiogenic shock (CS) are complex and resource intensive, particularly given the recent surge in the use of temporary mechanical circulatory support (tMCS)..

Perfusfind S.L.

Abstract Abstract Objectives:  To investigate whether severe hyperoxia predisposes to end-organ complications and whether these complications contribute to in-hospital mortality among cardiogenic shock (CS) patients supported in veno-arterial extracorporeal membrane..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion caused by primary cardiac failure, in which the heart cannot generate sufficient output despite adequate preload and is associated..

Perfusfind S.L.

Abstract Background Mixed cardiogenic and septic shock has been shown to have a higher mortality than cardiogenic shock alone and presents a unique hemodynamic phenotype. Objectives This study aimed to..

Perfusfind S.L.

Abstract Objectives To describe outcomes in patients who received venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock and to evaluate outcomes following programmatic changes. Design A retrospective cohort study. Setting..

Perfusfind S.L.

Abstract Background: Severe poisoning can lead to catastrophic cardiovascular collapse, often progressing to multiorgan failure and death. While intensive supportive care and pharmacological intervention remain the cornerstone of management, cases of..

Perfusfind S.L.

Abstract Background A systemic inflammatory response can contribute to poor outcomes in an advanced stage of cardiogenic shock (CS). We investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using..

Perfusfind S.L.

Abstract Background Immediate initiation of extracorporeal membrane oxygenation (ECMO) has not demonstrated benefit in individuals diagnosed with cardiogenic shock based on the presence of hypotension. The relationship between other hemodynamic..

Perfusfind S.L.

Abstract Background The microaxial flow pump (mAFP) improves survival in selected patients with ST-segment elevation myocardial infarction–induced cardiogenic shock (STEMI-CS). Understanding the impact on cardiac output (CO), cardiac power output..

Perfusfind S.L.

Abstract We investigated echocardiographic and hemodynamic effects of intraaortic balloon pump (IABP) in 26 patients with cardiogenic shock on veno-arterial membrane oxygenation (VA ECMO). Our study demonstrated an 8.1% increase..

Perfusfind S.L.

Abstract While iterative developments have improved outcomes of patients with myocardial infarction, mortality in patients with acute myocardial infarction cardiogenic shock (AMI-CS) remains stubbornly high. Several promising treatments have ultimately..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) in acute myocardial infarction (AMI) is a life-threatening syndrome characterized by systemic hypoperfusion that can quickly progress to multiorgan failure and death. Various devices and configurations..

Perfusfind S.L.

Abstract Background Clinical evidence regarding predictors of successful weaning from mechanical circulatory support (MCS) is lacking. This study aimed to create a simple risk score to predict successful weaning from..

Perfusfind S.L.

Abstract The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support (MCS) is a common treatment in patients with cardiogenic shock (CS) but is associated with high..

Perfusfind S.L.

Abstract Background Veno-Arterial Extracorporeal Life Support (VA ECMO) is a critical intervention for patients with cardiogenic shock, serving as bridge to recovery, transplantation, or long-term therapies. The complexity of VA..

Perfusfind S.L.

Abstract Background The impact of intra-aortic balloon pump (IABP) on survival and successful bridging to heart replacement therapies (HRT) in patients with heart failure–cardiogenic shock (HF-CS) remains unclear. Objectives The..